Financial Review: Nutriband (NASDAQ:NTRB) and Tempest Therapeutics (NASDAQ:TPST)

Nutriband (NASDAQ:NTRB) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Earnings & Valuation

This table compares Nutriband and Tempest Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.14 million	23.48	-$10.48 million	($3.07)	-1.34
Tempest Therapeutics	N/A	N/A	-$26.26 million	($6.64)	-0.28

Nutriband has higher revenue and earnings than Tempest Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nutriband and Tempest Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-560.89%	-133.22%	-114.00%
Tempest Therapeutics	N/A	-309.60%	-115.81%

Analyst Ratings

This is a breakdown of current ratings for Nutriband and Tempest Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1	1	0	0	1.50
Tempest Therapeutics	1	0	0	1	2.50

Volatility and Risk

Nutriband has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -2, meaning that its share price is 300% less volatile than the S&P 500.

Institutional and Insider Ownership

19.7% of Nutriband shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Nutriband beats Tempest Therapeutics on 7 of the 12 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.